• About Us
    • Our Company
    • Management Team
    • Board of Directors
    • Clinical Advisory Board
  • Product Candidates
  • Recent News
    • Press Releases
    • Research + Whitepapers
    • News
  • Contact Us
First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis

First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis

by NImmune Biopharma | May 2, 2023 | Research and White Papers

Psoriasis (PsO) is a complex immune-mediated disease that afflicts 100 million people. Omilancor is a locally-acting, small molecule that selectively activates the Lanthionine Synthetase C-like 2 (LANCL2) pathway, resulting in immunoregulatory effects at the...
NImmune Biopharma Launches with Phase III-Ready Asset Gained from Landos Biopharma

NImmune Biopharma Launches with Phase III-Ready Asset Gained from Landos Biopharma

by NImmune Biopharma | Mar 22, 2023 | News

Virginia life sciences entrepreneur Josep Bassaganya-Riera’s latest company NImmune Biopharma launched with an eye on a potential New Drug Application for its Phase III-ready experimental therapeutic for ulcerative colitis. NImmune Biopharma’s lead asset is...
Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitisand Crohn’s Disease

Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitisand Crohn’s Disease

by NImmune Biopharma | Mar 22, 2023 | Press Release

Download Press Release — Led by Dr. Bassaganya-Riera and a team of seasoned industry executives, NImmune is developing later-stage precision therapies addressing multiple autoimmune diseases, starting with Ulcerative Colitis (UC) and Crohn’s disease (CD) — NImmune’s...
Next Entries »

Recent Posts

  • NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026
  • NImmune Biopharma to Present at DDW’25 the First Ever Head-to-Head Clinical and Translational Results for Omilancor Versus Leading Anti-TL1A in IBD Showing Superiority and Complementarity
  • The NIMML Institute and NImmune Biopharma Showcase How the TITAN-X A.I. Platform has Accelerated Therapeutic Development in the Annual Review of Biomedical Data Science
  • NIMML Institute to Present Novel Clinical and Translational Data of Omilancor in Ulcerative Colitis Patients at Digestive Disease Week 2025
  • The NIMML Institute and NImmune Biopharma Announce Publication of Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus, in Clinical and Translational Science

Recent Comments

No comments to show.
  • About Us
  • Management Team
  • Board of Directors
  • Clinical Advisory Board
  • Product Candidates
  • Contact Us

Copyright © 2025 NImmune Biopharma